At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 134 enrolled
Drug / intervention
Tc99m tilmanoceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
In Brief
A Phase 2 clinical trial evaluating Tc99m tilmanocept for Rheumatoid Arthritis. Completed, enrolled 134 participants across 7 sites.
Detailed Summary
This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMay 2021
First PostedJul 2021
Primary CompletionJan 2022
TodayJul 2026
First PostedJul 1, 2021
Enrollment StartMay 27, 2021
Primary CompletionJan 21, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.0 years ago
Interventions
Tc99m tilmanoceptdrug
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.